Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, has appointed Barry Ivin as Site Director of Aerie’s new manufacturing plant in Athlone, Ireland.
On 9 January 2017, Aerie entered into a lease agreement with Ireland’s Industrial Development Agency for the Athlone site.
Mr Ivin will be responsible for leadership and direction over the build-out and validation of the plant and, if Aerie receives regulatory approval, future manufacturing operations for commercial product supply.
He has significant site leadership and engineering experience, and was most recently employed by Genzyme Ireland Limited (Sanofi), Waterford.Mr Ivin holds a Chemical Engineering undergraduate degree from University of South Wales and a Masters of Business Administration from the Graduate School of Business, University College Dublin.Read More
World’s largest society for regulatory professionals increases investment in Europe20 Apr 2017
Fujifilm increases production capacity and establishes new process development facilities19 Apr 2017
Nivalis Therapeutics and Alpine Immune Sciences agree to merge19 Apr 2017